Helperby Therapeutics

Antimicrobial resistance (AMR) is one of the biggest threats facing the world but arguably not enough is being done by both pharma companies and governments around the world. Read more


A new collaboration between the University of California, Los Angeles and biopharmaceutical company Helperby is looking to develop the next generation of combination antibiotics. Read more


British biopharmaceuticals company, Helperby Therapeutics, has developed a sustainable solution to combat antimicrobial resistance — Antibiotic Resistance Breakers (ARBs) — which may reach the market as early as 2020. Read more